GO:0043122 regulation of canonical NF-kappaB signal transduction: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0043122 describes any process that modulates the canonical NF-kappaB signaling cascade, a central inflammatory and immune-regulatory pathway.
• Canonical NF-kappaB activation depends on IKK-mediated phosphorylation and degradation of IkappaB inhibitors, releasing NF-kappaB dimers to enter the nucleus [1,8].
• Dysregulated regulation of canonical NF-kappaB signaling is implicated in cancer, inflammatory diseases, ischemia/reperfusion injury, and psoriasis [1,6,7,8].
• Key regulators include IKBKB, IKBKG, NFKBIA, RELA, and upstream receptors such as IL-34 and CD200 [1,6,7].
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal dissection of GO:0043122 regulators [1,8].
• EDITGENE provides end-to-end CRISPR cell model and library screening services to study canonical NF-kappaB regulation [1,8].
Description
GO:0043122, regulation of canonical NF-kappaB signal transduction, is a biological process that encompasses any molecular event modulating the canonical NF-kappaB signaling cascade. This pathway is a master regulator of innate and adaptive immunity, inflammation, cell survival, and proliferation, and its dysregulation underlies numerous human pathologies [1,8]. Understanding how the canonical NF-kappaB cascade is controlled is therefore essential for both basic immunology and therapeutic development [1,2].
regulation of canonical NF-kappaB signal transduction At A Glance
| GO ID | GO:0043122 |
|---|---|
| GO term | regulation of canonical NF-kappaB signal transduction |
| Ontology | biological_process |
| Synonym | regulation of I-kappaB kinase/NF-kappaB cascade; regulation of I-kappaB kinase/NF-kappaB signaling |
| Major function | Modulation of the canonical NF-kappaB signaling cascade, controlling inflammatory and immune responses. |
| Key upstream activators | TNF-alpha, IL-1beta, TLR ligands, IL-34, and CD200 [1,6,7]. |
| Core kinases | IKKalpha, IKKbeta, and IKKgamma (NEMO) [1,8]. |
| Major transcription factors | RELA (p65), RELB, NFKB1 (p50), NFKB2 (p52) [1,8]. |
| Disease relevance | Cancer, inflammatory bowel disease, psoriasis, myocardial ischemia/reperfusion injury [1,6,7,8]. |
What Is GO:0043122?
According to QuickGO, GO:0043122 is defined as any process that modulates the canonical NF-kappaB signaling cascade. It includes positive and negative regulation of the I-kappaB kinase/NF-kappaB cascade, which is triggered by pro-inflammatory cytokines, pathogen-associated molecular patterns, and antigen receptors. The canonical pathway is distinguished from the non-canonical NF-kappaB pathway by its reliance on IKKbeta and IkappaBalpha degradation [2,3].
Why Is regulation of canonical NF-kappaB signal transduction Important in Cell Biology?
The regulation of canonical NF-kappaB signal transduction is critical because it determines the intensity and duration of inflammatory and immune responses, and its aberrant activation or inhibition contributes to cancer, autoimmune diseases, and tissue injury [1,8]. Targeting this pathway has emerged as a promising therapeutic strategy, with multiple inhibitors in clinical development.
• Controls expression of pro-inflammatory cytokines, chemokines, and adhesion molecules.
• Regulates cell survival and apoptosis, influencing tumorigenesis.
• Modulates innate and adaptive immune cell activation and differentiation [1,2].
• Implicated in myocardial ischemia/reperfusion injury via IL-34-NF-kappaB signaling.
• Involved in psoriasis pathogenesis through gut microbiota-derived genistein and CD200-mediated NF-kappaB inhibition.
• Enhances STING signaling by altering microtubule-mediated STING trafficking.
• Associated with immune-hot and immune-cold tumor microenvironments and immunotherapy response.
• Provides targets for anti-inflammatory and anti-cancer drug development.
• Essential for understanding non-canonical NF-kappaB crosstalk and specificity [2,3].
• Enables CRISPR-based functional genomics to identify novel regulators [1,8].
What Happens During regulation of canonical NF-kappaB signal transduction?
Receptor Proximal Activation
In simple terms: Signals from outside the cell turn on the pathway.
Canonical NF-kappaB signaling is initiated when ligands such as TNF-alpha, IL-1beta, or pathogen components bind to receptors including TNFR, IL-1R, and TLRs. This triggers recruitment of adaptor proteins like MyD88, TRADD, and TRAF family members, leading to activation of the IKK complex [1,8].
IKK Complex Activation and IkappaB Phosphorylation
In simple terms: The IKK complex tags inhibitor proteins for destruction.
The IKK complex, composed of IKKalpha, IKKbeta, and NEMO (IKBKG), phosphorylates IkappaB proteins (e.g., NFKBIA) at specific serine residues, marking them for ubiquitination and proteasomal degradation [1,8]. This step is a key regulatory node in GO:0043122.
NF-kappaB Nuclear Translocation and DNA Binding
In simple terms: NF-kappaB moves into the nucleus to turn on genes.
Degradation of IkappaB releases NF-kappaB dimers, primarily p50/RELA, which translocate to the nucleus and bind kappaB DNA elements to activate transcription of target genes [1,8]. This transcriptional response is the functional output of canonical NF-kappaB signaling.
Negative Feedback and Termination
In simple terms: The pathway has brakes to prevent excessive inflammation.
NF-kappaB activation induces its own inhibitors, including NFKBIA and A20 (TNFAIP3), which terminate the signal and prevent chronic inflammation [1,8]. Dysregulation of these feedback loops contributes to autoimmune and malignant diseases.
Crosstalk with Other Signaling Pathways
In simple terms: NF-kappaB talks to other cellular pathways.
Canonical NF-kappaB signaling intersects with STING, MAPK, and PI3K/AKT pathways, modulating outcomes such as interferon responses and cell survival [4,8]. This crosstalk fine-tunes the regulation of canonical NF-kappaB signal transduction.
Key Genes Involved in GO:0043122 regulation of canonical NF-kappaB signal transduction
The following genes encode core components and regulators of the canonical NF-kappaB signaling cascade, and are frequently studied using CRISPR-based approaches.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RELA | NF-kappaB transcription factor subunit p65 | Central effector of canonical NF-kappaB target gene expression [1,8] |
| NFKB1 | NF-kappaB transcription factor subunit p50 | DNA-binding partner of RELA; regulates inflammatory genes [1,8] |
| IKBKB | IkappaB kinase beta | Essential kinase for IkappaB phosphorylation and NF-kappaB activation [1,8] |
| IKBKG | NEMO, regulatory subunit of IKK complex | Scaffold for IKK complex; mutations cause immunodeficiency |
| NFKBIA | IkappaB alpha inhibitor | Rapid negative feedback regulator; degradation releases NF-kappaB [1,8] |
| TNF | Tumor necrosis factor | Pro-inflammatory cytokine that activates canonical NF-kappaB |
| IL1B | Interleukin-1 beta | Cytokine that triggers canonical NF-kappaB via IL-1R |
| MYD88 | Adaptor protein for TLR/IL-1R | Links innate immune sensing to IKK activation |
| TRADD | TNFR-associated death domain | Adaptor for TNFR1-mediated NF-kappaB activation |
| TRAF6 | E3 ubiquitin ligase | Mediates K63-linked ubiquitination for IKK activation |
| TNFAIP3 | A20, negative regulator | Terminates NF-kappaB signaling; frequently mutated in lymphoma [1,8] |
| IL34 | Interleukin-34 | Activates NF-kappaB in macrophages; aggravates myocardial injury |
| CD200 | Immunoregulatory receptor | Inhibits NF-kappaB in psoriasis model |
| STING1 | Stimulator of interferon genes | Crosstalk with NF-kappaB; affects microtubule trafficking |
| NFKB2 | NF-kappaB p100/p52 | Non-canonical subunit with crosstalk to canonical pathway [2,3] |
| REL | c-Rel transcription factor | Regulates immune and inflammatory gene expression |
| CHUK | IKKalpha kinase | Participates in canonical and non-canonical NF-kappaB regulation [1,2] |
How Is regulation of canonical NF-kappaB signal transduction Regulated?
The canonical NF-kappaB pathway is tightly regulated by post-translational modifications, including phosphorylation, ubiquitination, and acetylation of IKK subunits and NF-kappaB dimers [1,8]. Negative feedback loops involving NFKBIA, TNFAIP3, and CYLD are essential for preventing excessive inflammation. Additionally, crosstalk with non-canonical NF-kappaB signaling provides context-dependent modulation [2,3].
regulation of canonical NF-kappaB signal transduction and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| RELA | Multiple myeloma, lymphoma | Knockout or point mutation in cancer cell lines [1,8] |
| NFKBIA | Hodgkin lymphoma, glioblastoma | Knock-in of patient mutations [1,8] |
| TNFAIP3 | Lymphoma, autoimmune disease | Knockout in immune cells |
| IL34 | Myocardial ischemia/reperfusion injury | Overexpression in macrophages |
| CD200 | Psoriasis | Knockout or overexpression in keratinocytes |
Cancer
Aberrant activation of canonical NF-kappaB signaling is a hallmark of many cancers, promoting proliferation, survival, and metastasis. Mutations in NFKBIA, TNFAIP3, and IKBKB are found in lymphoid malignancies, and NF-kappaB activation correlates with poor prognosis [1,8].
Inflammatory and Autoimmune Diseases
Dysregulated canonical NF-kappaB signaling drives chronic inflammation in rheumatoid arthritis, inflammatory bowel disease, and psoriasis [1,7]. In a mouse model, gut-derived genistein alleviated psoriatic inflammation via CD200-mediated NF-kappaB inhibition.
Cardiovascular Injury
IL-34-NF-kappaB signaling aggravates myocardial ischemic/reperfusion injury by facilitating macrophage recruitment and polarization. Targeting this axis may reduce cardiac damage after infarction.
Tumor Microenvironment and Immunotherapy
Single-cell and spatial analysis of immune-hot and immune-cold tumors identified fibroblast subtypes associated with distinct immunological niches and positive immunotherapy response, implicating NF-kappaB-related signaling. NF-kappaB activation also enhances STING signaling by altering microtubule-mediated STING trafficking.
From regulation of canonical NF-kappaB signal transduction-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is IKBKB required for canonical NF-kappaB activation? | IKBKB knockout cell line [1,8] |
| Does a specific NFKBIA mutation impair IkappaB degradation? | Point mutation knock-in |
| Can a tagged RELA track nuclear translocation? | Knock-in of fluorescent tag |
| Does overexpression of IL34 activate NF-kappaB in macrophages? | Overexpression cell model |
| Which genes regulate NF-kappaB in a genome-wide screen? | CRISPR library screening [1,8] |
| Does CD200 inhibit NF-kappaB in psoriasis? | Knockout and overexpression in keratinocytes |
How to Study the regulation of canonical NF-kappaB signal transduction Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Gene requirement for NF-kappaB activation | Identify novel regulators [1,8] |
| RNA-seq | Transcriptional changes | NF-kappaB target gene expression |
| Phospho-proteomics | Phosphorylation of IKK/IkappaB | Quantify pathway activation |
| Live-cell imaging | RELA nuclear translocation | Real-time pathway dynamics [1,4] |
| Luciferase reporter assay | NF-kappaB transcriptional activity | High-throughput screening |
| Co-immunoprecipitation | Protein-protein interactions | IKK complex assembly |
| Flow cytometry | Immune cell polarization | Macrophage recruitment |
| Spatial transcriptomics | Tumor microenvironment niches | Immunotherapy response |
CRISPR Knockout Screening
Genome-wide CRISPR knockout screens can identify novel regulators of canonical NF-kappaB signaling by selecting for cells with altered NF-kappaB-dependent reporter activity [1,8].
Transcriptional Profiling
RNA-seq after pathway stimulation reveals NF-kappaB target gene signatures and can quantify the impact of genetic perturbations on GO:0043122 [1,8].
Phospho-Proteomics
Mass spectrometry-based phosphoproteomics measures IKK and IkappaB phosphorylation dynamics, providing direct readouts of canonical NF-kappaB activation.
Imaging of NF-kappaB Translocation
Live-cell imaging with fluorescently tagged RELA allows real-time monitoring of nuclear translocation, a key step in canonical NF-kappaB signaling [1,4].
How CRISPR Can Be Used to Study GO:0043122 regulation of canonical NF-kappaB signal transduction
Knockout
CRISPR knockout of core genes such as IKBKB, RELA, or NFKBIA abolishes or enhances canonical NF-kappaB signaling, providing causal evidence for their role in GO:0043122 [1,8].
Point Mutation
Point mutations can mimic patient-derived variants in NFKBIA or IKBKB, allowing assessment of their impact on IkappaB degradation and NF-kappaB activation.
Knock-in
Knock-in of epitope tags or fluorescent reporters into endogenous RELA or NFKB1 loci enables tracking of NF-kappaB dynamics in live cells.
Overexpression
Overexpression of activators like IL34 or inhibitors like CD200 can modulate canonical NF-kappaB signaling and model disease-associated states [6,7].
How EDITGENE Supports regulation of canonical NF-kappaB signal transduction Research
Researchers studying regulation of canonical NF-kappaB signal transduction-related genes often need to determine whether a candidate gene is causally involved in pathway modulation. EDITGENE provides a comprehensive suite of CRISPR services to generate precisely engineered cell models for such functional studies.
Contact EDITGENE today to design your custom CRISPR model for regulation of canonical NF-kappaB signal transduction research.
Frequently Asked Questions About regulation of canonical NF-kappaB signal transduction
What is GO:0043122?
GO:0043122 is the Gene Ontology term for regulation of canonical NF-kappaB signal transduction, describing any process that modulates the canonical NF-kappaB signaling cascade.
What genes are involved in regulation of canonical NF-kappaB signal transduction?
Key genes include RELA, NFKB1, IKBKB, IKBKG, NFKBIA, TNF, IL1B, MYD88, TRAF6, and TNFAIP3 [1,8].
How is canonical NF-kappaB signaling activated?
It is activated by ligands such as TNF-alpha and IL-1beta, which trigger IKK-mediated phosphorylation and degradation of IkappaB, releasing NF-kappaB dimers to enter the nucleus [1,8].
What diseases are associated with dysregulated canonical NF-kappaB signaling?
Cancer, inflammatory bowel disease, psoriasis, rheumatoid arthritis, and myocardial ischemia/reperfusion injury [1,6,7,8].
What is the difference between canonical and non-canonical NF-kappaB pathways?
The canonical pathway depends on IKKbeta and IkappaBalpha degradation, while the non-canonical pathway relies on NF-kappaB-inducing kinase (NIK) and p100 processing [2,3].
How can CRISPR be used to study GO:0043122?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of genes in the canonical NF-kappaB cascade [1,8].
What methods measure canonical NF-kappaB activity?
Luciferase reporter assays, phospho-proteomics, RNA-seq, and live-cell imaging of RELA translocation [1,4].
What is the role of IL-34 in NF-kappaB signaling?
IL-34 activates NF-kappaB in macrophages and aggravates myocardial ischemic/reperfusion injury.
How does CD200 affect NF-kappaB in psoriasis?
CD200 mediates NF-kappaB inhibition and alleviates psoriatic inflammation in mice.
Does NF-kappaB crosstalk with STING signaling?
Yes, NF-kappaB activation enhances STING signaling by altering microtubule-mediated STING trafficking.
Conclusion
GO:0043122, regulation of canonical NF-kappaB signal transduction, is a fundamental biological process controlling inflammation, immunity, and cell survival. Its dysregulation is linked to cancer, autoimmune diseases, and tissue injury, making it a prime therapeutic target [1,8]. CRISPR-based models and functional genomics are indispensable for dissecting its regulatory mechanisms and identifying new drug targets [1,8].
References
- 1. Yu H et al.. 2020. Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study.. Signal Transduct Target Ther 5(1):209 PMID: 32958760
- 2. Sun SC. 2017. The non-canonical NF-κB pathway in immunity and inflammation.. Nat Rev Immunol 17(9):545-558 PMID: 28580957
- 3. Sun SC. 2011. Non-canonical NF-κB signaling pathway.. Cell Res 21(1):71-85 PMID: 21173796
- 4. Zhang L et al.. 2023. NF-κB activation enhances STING signaling by altering microtubule-mediated STING trafficking.. Cell Rep 42(3):112185 PMID: 36857187
- 5. Jenkins BH et al.. 2025. Single cell and spatial analysis of immune-hot and immune-cold tumours identifies fibroblast subtypes associated with distinct immunological niches and positive immunotherapy response.. Mol Cancer 24(1):3 PMID: 39757146
- 6. Zhuang L et al.. 2023. Interleukin-34-NF-κB signaling aggravates myocardial ischemic/reperfusion injury by facilitating macrophage recruitment and polarization.. EBioMedicine 95:104744 PMID: 37556943
- 7. Le D et al.. 2026. Gut-derived genistein from Parabacteroides distasonis alleviates psoriatic inflammation via CD200-mediated NF-κB inhibition in mice.. Gut Microbes 18(1):2701386 PMID: 42461117
- 8. Deka K et al.. 2023. Transcriptional Regulation during Aberrant Activation of NF-κB Signalling in Cancer.. Cells 12(5) PMID: 36899924
